Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2

Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.

Materials and Methods. Model of Burden of T2DM has been created in Microsoft Excel 2010 program. Direct (costs of medicines, treatment of main T2DM complications — myocardial infarction, stroke, etc.) as well as indirect costs (GPD losses, disability related payments, etc.) were calculated. Complications’ rate was took from Federal Diabetes Register. Influence on Burden of T2DM was tested with the additional model which can calculate expenditures with different drugs including Soliqua SoloStar® usage.

Results. Direct medical costs with Soliqua SoloStar® usage were less in compare with insulin glargine 100 UI/ml on 23,5 % per year due to decreasing level of severe hypoglycemia and possible protective effect on complications of T2DM (better control). Total expenditures for Soliqua SoloStar® were less on 2,5 % annually, in the same time insulin glargine led to total cost increase by 18,4 % per year. So, difference between expenditures in case of Soliqua SoloStar® were less on appr 21 % vs insulin glargine 100 UI/ml. Budget saving is expected as 6,78 ml RUR per year / 1 000 patients in case of Soliqua SoloStar® usage.

Conclusion. Soliqua SoloStar® has economic benefits due to T2DM complications and severe hypoglycemia reduction risks.

1. International Diabetes Federation. IDF Diabetes, 8 ed. Brussels, Belgium: International Diabetes Federation, 2017. http://www.diabetesatlas.org обращение к ресурсу 02.01.2019.

2. Dedov I, Shestakova M, Benedetti MM, et al. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res Clin Pract. 2016;115:90-95. DOI: 10.1016/j.diabres.2016.02.010.

3. Dedov II, Kontsevaya AV, Shestakova MV, et al. Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation. Diabetes Mellitus. 2016;19(6):518-527 (In Russ). DOI: 10.14341/DM8153

4. Instrukciya po medicinskomu primeneniyu preparata Soliqua SoloStar®. (In Russ).] http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c5d73eb9-398a-45cf-920b-bdd7519f28d1&t=. Обращение к ресурсу 02.01.2019.

5. Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39(11):2026-2035.

6. Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care. 2016;39(11):1972-1980.

7. Protokol zasedaniya Komissii Minzdrava Rossii poformirovaniyu Perechnej lekarstvennyh preparatov dlya medicinskogo primeneniya i minimal’nogo assortimenta lekarstvennyh preparatov dlya okazaniya medicinskoj pomoshchi ot 18.07.2019 g., Moscow. (In Russ). https://www.rosminzdrav.ru/ministry/61/10/stranitsa-858/protokol-zasedaniya-komissii, обращение к ресурсу 01.08.2019.

8. Zyryanov SK, Dyakov IN. Economic perspectives of an effective diabetes mellitus type 2 control with fixed combination of basal insulin analog and GLP-1 agonist. Kachestvennaya klinjicheskaya praktika. 2019;2:4-15 (In Russ)]. DOI: 10.24411/2588-0519-2019-10068

9. Kolbin AS, Kurilev AA, Balikina YuE, et al. Economic evaluation of insulin therapy intensification for effective and safe control of Diabetes Mellitus type 2. Kachestvennaya klinicheskaya praktika. 2019;2:25-35 (In Russ). DOI: 10.24411/2588-0519-2019-10070

10. http://grls.rosminzdrav.ru, обращение к ресурсу 01.02.2019.

11. https://fas.gov.ru/documents/684978, обращение к ресурсу 03.04.2019.

12. Minzdrav Rossii, Federal’nyj fond obyazatel’nogo medicinskogo strahovaniya. Metodicheskie rekomendacii po sposobam oplaty medicinskoj pomoshchi za schet sredstv OMS na 2019 g. (protokol zasedaniya ot 12.11.2018 № 66/11/15). (In Russ). http://www.ffoms.ru/documents/the-orders-oms/etodicheskie-rekomendatsii-po-sposobam-oplaty-meditsinskoy-pomoshchi-za-schet-sredstv-obyazatelnogo/, обращение к ресурсу 01.03.2019.

13. Postanovlenie Pravitel’stva Rossijskoj Federacii ot 10.12.2018 №1506 «O programme gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoshchi na 2019 god i na planovyj period 2020 i 2021 godov». (In Russ). http://government.ru/docs/35025/, обращение к ресурсу 01.03.2019.

14. Erlikh AD, Gratsianskiy NA. Registry of acute coronary syndromes “RECORD-3” — characteristic of patients and treatment during initial hospitalization. Cardiology. 2016;4:16-24. (In Russ). DOI: 10.18565/cardio.2016.4.16-24

15. http://www.pfrf.ru/, обращение к ресурсу 01.03.2019.

16. http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/rates/46880c804a41fb53bdcebf78e6889fb6, обращение к ресурсу 01.03.2019/

17. Prikaz Minzdrava Rossii ot 01.07.2015 g. №404an «Ob utverzhdenii standarta specializirovannoj medicinskoj pomoshchi pri ostrom infarkte miokarda (s pod»emom segmenta ST elektrokardiogrammy) (s izmeneniyami ot 01.09.2017 g.)». (In Russ).

18. Prikaz Minzdrava Rossii ot 29.12.2012 g. №1740n «Ob utverzhdenii standarta specializirovannoj medicinskoj pomoshchi pri infarkte mozga». (In Russ).

19. Prikaz Minzdrava Rossii ot 24.12.2012 g. №1554n «Ob utverzhdenii standarta specializirovannoj medicinskoj pomoshchi pri serdechnoj nedostatochnosti». (In Russ).

20. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of nonsevere hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14(5):665-671. DOI: 10.1016/j.jval.2011.02.001

21. Federal’naya sluzhba gosudarstvennoj statistiki. Srednemesyachnaya nominal’naya nachislennaya zarabotnaya plata rabotnikov v celom po ekonomike Rossijskoj Federacii v 1991-2018 gg. (In Russ). http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/, обращение к ресурсу 01.02.2019 г.

22. Meier J, Anderson J, Wysham C, et al. Propensity-score matched patient-level comparison of iGlarLixi and basal-bolus regimen in patients with Type 2 Diabetes. — 786 EASD 2018 1—5 October Berlin, Germany.

23. Kobalava ZD, Kiyakbaev GК. Type 2 Diabetes and cardiovascular complications: is it possible to improve prognosis by glucose lowering therapy? Russian Journal of Cardiology. 2018;8:79-91. (In Russ). https://doi.org/10.15829/1560-4071-2018-8-79-91

24. Williams SA, Shi L, Brenneman SK, et al. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications. 2012;26(5):399-406. DOI: 10.1016/j.jdiacomp.2012.05.002